CRO M&As Show No Sign of Slowing Down
By Lisa Henderson. With all of the activity in CRO M&As the past three years, it’s slightly amazing that it continues — and that analysts don’t see it slowing down. In fact, investment analysts...
View ArticlePfizer’s AZ Bid Draws Mixed UK Reaction
The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK. Linda McCulloch of Britain’s biggest union, Unite, said the bid is “very worrying for...
View ArticleClik here to view.
Merger Mania: When the Music Stops
Clifford Kalb As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again, I suspect that we will shortly be entering a transition where the tone...
View ArticleClik here to view.
The Urge to Merge: Dealmaking Lessons from Pharma History
By Cliff Kalb. The major pressures hindering pharmaceutical industry success have not changed—payer constraints on drug costs, R&D productivity, an increasingly risk-averse regulatory climate,...
View ArticlePharma Leads the Way in M&A
The pharma, medical and biotech industry is the leading sector for M&A activity this year, Mergermarket‘s Q2 M&A stats reveal. The sector’s deals have been valued at US$252.5 bn, a 16.9%...
View ArticleClik here to view.
Pharm Exec’s Pharma Top 50 in Brief
The vigorous return of M&A activity this year brings us back to the question: is more size and scalable efficiencies the best solution to the declining market power of pharmaceuticals in an...
View ArticleClik here to view.
Pharm Exec's 2014 Dealmakers Outlook
After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday’s understudy, now gets top billing,...
View Article
